L

LifeMD, Inc. (LFMD)

NGM – Real vaqt narxi. Valyuta: USD

4.28

-0.11 (-2.51%)

Yopilishda: May 12, 2026, 4:00 PM EDT

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Barcha huquqlar himoyalangan.

Foydalanish shartlari

L

LifeMD, Inc. (LFMD)

NGM – Real vaqt narxi. Valyuta: USD

4.28

-0.11 (-2.51%)

Yopilishda: May 12, 2026, 4:00 PM EDT

07.05.2026

LifeMD, Inc. (LFMD) Q1 2026 Earnings Call Transcript

06.05.2026

LifeMD, Inc. (LFMD) Reports Q1 Loss, Tops Revenue Estimates

LifeMD, Inc. (LFMD) came out with a quarterly loss of $0.2 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to earnings of $0.01 per share a year ago.

06.05.2026

LifeMD Reports First Quarter 2026 Results

First quarter 2026 revenue of $50.2 million and adjusted EBITDA loss of $4.5 million, above and in line, respectively, with the Company's guidance. Gross margin increased approximately 420 basis points to 88%, versus the first quarter of 2025, reflecting favorable revenue mix and lower fulfillment costs.

27.04.2026

LifeMD to Report First Quarter 2026 Financial Results on May 6

NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, announces that it will report financial results for the three months ended March 31, 2026, after the close of the U.S. financial markets on May 6, 2026, and will host a conference call beginning at 4:30 p.m. Eastern time.

21.04.2026

LifeMD (LFMD) Soars 23.7%: Is Further Upside Left in the Stock?

LifeMD (LFMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

10.04.2026

LifeMD® Now Offering Eli Lilly and Company's Foundayo™ (orforglipron), a New GLP-1 Pill for Weight Management

LifeMD expands its weight management program with the addition of Foundayo, offering eligible patients an oral alternative to injectable GLP-1 therapies through LillyDirect® LifeMD expands its weight management program with the addition of Foundayo, offering eligible patients an oral alternative to injectable GLP-1 therapies through LillyDirect®

31.03.2026

LifeMD Offers Novo Nordisk's Industry-First Wegovy® Telehealth Subscription Program

Delivering up to $1,200 in annual patient savings on branded GLP-1 therapy, expanding LifeMD's collaboration with Novo Nordisk Delivering up to $1,200 in annual patient savings on branded GLP-1 therapy, expanding LifeMD's collaboration with Novo Nordisk

Videolar

No Data

There is no data to display

Press-relizlar

06.05.2026

LifeMD Reports First Quarter 2026 Results

First quarter 2026 revenue of $50.2 million and adjusted EBITDA loss of $4.5 million, above and in line, respectively, with the Company's guidance. Gross margin increased approximately 420 basis points to 88%, versus the first quarter of 2025, reflecting favorable revenue mix and lower fulfillment costs.

10.04.2026

LifeMD® Now Offering Eli Lilly and Company's Foundayo™ (orforglipron), a New GLP-1 Pill for Weight Management

LifeMD expands its weight management program with the addition of Foundayo, offering eligible patients an oral alternative to injectable GLP-1 therapies through LillyDirect® LifeMD expands its weight management program with the addition of Foundayo, offering eligible patients an oral alternative to injectable GLP-1 therapies through LillyDirect®

31.03.2026

LifeMD Offers Novo Nordisk's Industry-First Wegovy® Telehealth Subscription Program

Delivering up to $1,200 in annual patient savings on branded GLP-1 therapy, expanding LifeMD's collaboration with Novo Nordisk Delivering up to $1,200 in annual patient savings on branded GLP-1 therapy, expanding LifeMD's collaboration with Novo Nordisk

24.03.2026

LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock

NEW YORK, March 24, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced that its Board of Directors has authorized a cash dividend to holders of the Company's 8.875% Series A Cumulative Perpetual Preferred Stock (Nasdaq: LFMDP) equal to $0.5546875 per share.

Search stocks

LifeMD, Inc. (LFMD)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

LifeMD, Inc. (LFMD)

LifeMD, Inc. (LFMD) Q1 2026 Earnings Call Transcript

LifeMD, Inc. (LFMD) Reports Q1 Loss, Tops Revenue Estimates

LifeMD Reports First Quarter 2026 Results

LifeMD to Report First Quarter 2026 Financial Results on May 6

LifeMD (LFMD) Soars 23.7%: Is Further Upside Left in the Stock?

LifeMD® Now Offering Eli Lilly and Company's Foundayo™ (orforglipron), a New GLP-1 Pill for Weight Management

LifeMD Offers Novo Nordisk's Industry-First Wegovy® Telehealth Subscription Program

Videolar

No Data

Press-relizlar

LifeMD Reports First Quarter 2026 Results

LifeMD® Now Offering Eli Lilly and Company's Foundayo™ (orforglipron), a New GLP-1 Pill for Weight Management

LifeMD Offers Novo Nordisk's Industry-First Wegovy® Telehealth Subscription Program

LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock